ADNI Researchers and Industry Partners Developing Proteomic Profiles to Track Alzheimer's Disease

Biotechnology firms participating in the Alzheimer's Disease Neuroimaging Initiative have received plasma and CSF samples from ADNI participants and contributed funds for the processing of roughly 1,000 samples by biomarker discovery firm Rules-Based Medicine.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.